Osteoporosis

Latest

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.

Risks Associated With Denosumab Discontinuation

Risks Associated With Denosumab Discontinuation

Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.

FDA Requests Additional Data in Romosozumab Biologics License Application

FDA Requests Additional Data in Romosozumab Biologics License Application

The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.

Does Sedative Use Increase Repeat Fall Risk?

Does Sedative Use Increase Repeat Fall Risk?

Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.

ACP: Updated Osteoporosis Treatment Guidelines

ACP: Updated Osteoporosis Treatment Guidelines

An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.

Osteoporosis, Fracture Risk Elevated With Tuberculosis

Osteoporosis, Fracture Risk Elevated With Tuberculosis

Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.

Sign Up for Free e-Newsletters

CME Focus